Romidepsi (Istodax)
Targeted Therapy · Approved since 2009
Description
Romidepsin is a histone deacetylase (HDAC) inhibitor that has been evaluated in microsatellite stable (MSS) colorectal cancer patients who have progressed after standard treatments. This epigenetic modifier was originally developed for hematologic malignancies and has been explored in solid tumors including colorectal cancer. It represents an approach to modulate gene expression patterns in cancer cells through chromatin remodeling.
Mechanism of Action
Romidepsin selectively inhibits class I histone deacetylases (HDAC1, HDAC2, and HDAC3), leading to hyperacetylation of histones and subsequent reactivation of silenced tumor suppressor genes. This epigenetic modification can restore normal cell cycle control and promote apoptosis in cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Istodax |
| Category | Targeted Therapy |
 Status | Off-label |
| Administration | IV |
| Year Approved | 2009 |
| Clinical Trials | 3 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.